Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351631 | 0.85 | PARK7 (0.57) | PARK7MAPTRAB9ASMN1; SMN2MAOA | |
| SCHEMBL16649823 | 0.84 | PARK7 (0.48) | PARK7MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL350823 | 0.84 | PARK7 (0.54) | PARK7MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL16649916 | 0.79 | PARK7 (0.58) | PARK7MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL353742 | 0.79 | PARK7 (0.54) | PARK7MAPTRAB9ASMN1; SMN2MAOB | |
| SCHEMBL352240 | 0.79 | MAPT (0.43) | MAPTRAB9ASMN1; SMN2MAOAMAOB | |
| SCHEMBL353842 | 0.79 | PARK7 (0.50) | PARK7MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL351919 | 0.79 | PARK7 (0.50) | PARK7MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL16649950 | 0.78 | PARK7 (0.46) | PARK7 | |
| SCHEMBL666087 | 0.78 | PARK7 (0.64) | PARK7MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | claimed |
| EP-2411376-A1 | INHIBITORS OF NF-KB | Profectus Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | PARK7 3327/4885MAPT 2761/4885RAB9A 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.